A Single-center Experience and Review of the Literature: 64 Cases of Phyllodes Tumors to Better Understand Risk Factors and Disease Management

Lightner, Amy L.; Shurell, Elizabeth; Dawson, Nicole A.; Omidvar, Yasaman; Foster, Nova

doi:10.1177/000313481508100336

Cited by 10 publications

(13 citation statements)

References 33 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PT is a rare fibroepithelial tumor accounting for less than 1 % of all breast neoplasms [ 1 , 2 ]. They usually arise in women between ages 35 and 55 years and are classified as benign, borderline and malignant [ 2 , 3 ]. Malignant types present approximately 20 % of all cases [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

“…Metastatic PTs mainly develop from 3 to 10 years after the inital therapy, but they can be delayed or occur as soon as synchronous presentation [ 11 ]. The lung is the most common site of metastatic spread [ 2 , 3 , 15 ]. Only a few cases of PT metastatic to bone have been reported [ 6 ] with 2 cases involving the iliac bone [ 6 , 7 ] and 1 case involving the femur [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Both radiotherapy and chemotherapy are recommended in metastatic PTs [ 2 , 6 , 16 ]. Ifosfamide is the most active agent [ 16 ]; antiestrogen therapy is not indicated [ 3 , 16 ]. Some studies revealed several potentially targetable pathway including epidermal growth factor receptor, angiogenesis (vascular endothelial growth factor A, angiopoietin-2, vascular cell adhesion molecule 1, platelet- derived growth factor receptor A, pituitary tumor-transforming1) and immunotherapy (programmed cell death protein 1, programmed death-ligand 1) for patients with locally advanced or metastatic tumors [ 4 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…Phyllodes tumors (PTs) are rare fibroepithelial tumors accounting for less than 1 % of all breast neoplasms [ 1 , 2 ]. They are classified as benign, borderline and malignant [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Bone metastasis from malignant phyllodes breast tumor: report of two cases

et al. 2016

View full text Add to dashboard Cite

Background: Phyllodes tumors are rare fibroepithelial tumors accounting for less than 1 % of all breast neoplasms. They are malignant in 20 % of cases. Only a few cases of malignant phyllodes tumors metastatic to bone have been reported. Case presentation: Case 1: A 40 year-old white woman presented with three-week history of pain and functional impairment of the left lower limb. Her clinical past was remarkable for previous left mastectomy and radiotherapy for malignant phyllodes tumor performed one year ago. Computed tomography revealed a moth-eaten appearance of the left femoral head. The patient underwent computed guided femoral head biopsy. Pathological findings were consistent with metastatic malignant phyllodes tumor. The patient received ifosfamide and adriamycin chemotherapy. She is doing well without any evidence of progression on her imaging follow-up after 8 months. Case 2: A 48 year-old white woman, with history of bilateral mastectomy and radiotherapy for malignant phyllodes tumor performed one and two year ago, presented with four-week left lower quadrant abdominal pain. Computed tomography and magnetic resonance imaging revealed a solid aggressive osteolytic mass of the left iliac bone with extensive soft tissue invasion. Biopsy of the tumor was performed and showed a sarcomatous proliferation consistent with metastatic malignant phyllodes tumor. The patient received the same chemotherapy regimen as in the first case but without any response on her imaging follow up after 6 months. Conclusion: Malignant phyllodes tumor is a rare and aggressive fibroepithelial neoplasm. An accurate diagnosis of metastases should be based on clinicopathological correlation allowing exclusion of differential diagnoses. The goal of successful managing this tumor is early detection and complete resection prior to dissemination.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Phyllodes tumors (PTs) are rare fibroepithelial tumors accounting for less than 1 % of all breast neoplasms [ 1 , 2 ]. They are classified as benign, borderline and malignant [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bone metastasis from malignant phyllodes breast tumor: report of two cases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Phyllodes tumors most often arise in patients in the 5 th decade of life and vastly more commonly in females [ 1 ]. They clinically present as a rapidly growing mass based in the breast, which is an important clue for diagnosis even if pathological diagnosis is inconclusive [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

Enormous, rapidly growing breast mass

et al. 2015

View full text Add to dashboard Cite

BackgroundSigns and symptoms of a rapidly enlarging breast mass are not only important for all clinicians to recognize and assess, but also are not uncommon occurrences. We describe a similar but unique case that developed into an enormous, 36 cm exophytic mass.Case presentationA 51-year-old woman with history of psychiatric conditions presented for signs and symptoms of sepsis. It was determined that the source was an enormous 36 cm mass originating from the breast/chest wall. After stabilizing the patient with antibiotics, she underwent successful resection. Surgical margins were positive, and histopathology demonstrated bland spindle cells with stromal overgrowth. Together with clinical and histopathological information, the patient was diagnosed with a phyllodes tumor.ConclusionDifferential diagnosis of rapidly growing breast masses is discussed, which are not uncommon occurrences in clinical medicine. One etiology, phyllodes tumors, can grow into large, exophytic masses as described. Oncologic treatment is discussed, usually consisting of surgery with postoperative radiotherapy for high-risk features.

show abstract